Stocks · News reference

Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine

Sep 30, 2026, 12:40 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 30, 2026, 12:40 PM
Checked: Sep 30, 2026, 12:40 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 6, 2026, 12:57 PMBenzinga Newsdesk
Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8
Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center. The meeting will take place October 6–8, 2026, on MD
ERNA
BenzingaSep 29, 2026, 1:18 PMBenzinga Newsdesk
Ernexa Therapeutics To Present At Cell & Gene Meeting On The Mesa On October 6; Says ERNA-101 IND Submission On Track For 2026
ERNA
BenzingaSep 15, 2026, 12:42 PMBenzinga Newsdesk
Ernexa Therapeutics Says ERNA-201 Showed Reduced Disease Severity vs. Untreated Controls In Preliminary Collagen-Induced Arthritis Mouse Study; Pauses ERNA-201 Preclinical Spending To Prioritize ERNA-101 IND Submission In Q4 2026
ERNA